Tests a non-surgical radiation treatment for kidney tumors
Tests stereotactic radiation for kidney tumors in people who may not suit surgery.
Plain-language title generated from the registry record
Registry title: SABR for Renal Tumors
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- University Health Network - Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT03747133
- Record updated
- 4 June 2026
- Original description
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.Read full original descriptionShow less
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.
Inclusion: Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm; Histological or radiological diagnosis of renal tumor; Inoperable: High risk for surgery or declined surgery; ECOG performance status of 0-3.
Exclusion: Systemic therapy (except endocrine therapy) within 60 days prior to SABR; Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney; Patients with end stage renal failure > 4(KDOQI guidelines); Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis; ≥5 active metastases.